Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Market Closed 06-26 16:00:00 EDT

3.17

+0.02

+0.63%

盘后3.17

+0.000.00%

19:17 EDT

High3.17	Low3.15	Vol14.00M
Open3.15	D1 Closing3.15	Amplitude0.63%
Mkt Cap814.09M	Tradable Cap751.29M	Total Shares256.81M
T/O44.27M	T/O Rate5.91%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":3.17,"timestamp":1782504000000,"preClose":3.15,"halted":0,"volume":13995109,"hourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"19:17 EDT","volume":723699,"amount":2294071.995508,"timestamp":1782515833296,"change":0,"changeRate":0,"amplitude":0.003155},"delay":0,"changeRate":0.006349206349206355,"floatShares":237000000,"shares":256810500,"eps":-0.033486,"marketStatus":"Market Closed","change":0.02,"latestTime":"06-26 16:00:00 EDT","open":3.15,"high":3.17,"low":3.15,"amount":44268782.979549,"amplitude":0.006349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.033486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":3.15,"preHourTrading":{"tag":"盘前","latestPrice":3.1501,"preClose":3.15,"latestTime":"09:00 EDT","volume":3800,"amount":11972.180059999999,"timestamp":1782478818868,"change":0.0001,"changeRate":0.000032,"amplitude":0.000381},"postHourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"19:17 EDT","volume":723699,"amount":2294071.995508,"timestamp":1782515833296,"change":0,"changeRate":0,"amplitude":0.003155},"volumeRatio":1.35518,"impliedVol":3.1251,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/ESPR/","defaultTab":"news","newsList":[{"id":"2644767433","title":"Esperion Therapeutics announces special shareholder meeting on merger agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767433","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767433?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:01","pubTimestamp":1781640106,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics scheduled a virtual special stockholder meeting for July 8, 2026.Shareholders will vote on adopting the merger agreement under which Essence MergerCo will merge into Esperion, leaving Esperion as a wholly owned unit of Essence Parent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLcbJkvp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209492","title":"Esperion Therapeutics announces shareholder meeting on merger agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209492","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209492?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:02","pubTimestamp":1781035328,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics will hold a virtual special meeting of stockholders on July 8, 2026.Stockholders will vote on adopting the merger agreement under which Essence MergerCo will merge into Esperion, leaving Esperion as a wholly owned unit of Essence Parent.The deal has received German antitrust clearance, effective June 2, 2026.Closing still hinges on remaining conditions, including US antitrust waiting periods and stockholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL44msfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642043491","title":"Green steel, grey area: The definition vacuum fracturing a critical market","url":"https://stock-news.laohu8.com/highlight/detail?id=2642043491","media":"Fastmarkets","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642043491?lang=en_us&edition=fundamental","pubTime":"2026-06-09 12:00","pubTimestamp":1780977600,"startTime":"0","endTime":"0","summary":"Lack of standardisation, certifications and market practises is creating growing uncertainty across green steel markets, with implications for pricing, procurement and credibility.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/green-steel-grey-area-the-definition-vacuum-fracturing-a-critical-market/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/green-steel-grey-area-the-definition-vacuum-fracturing-a-critical-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["ESPR","LU2098885051.SGD","LU1303367103.USD","EAC","BK4137","IAA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640642379","title":"Esperion Therapeutics shareholders approve 7 million-share increase to 2022 equity plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640642379","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640642379?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:23","pubTimestamp":1780345422,"startTime":"0","endTime":"0","summary":"Esperion held its annual shareholder meeting on May 28, 2026.Shareholders passed an amendment to the 2022 stock option and incentive plan, lifting the share pool by 7 million shares.Shareholders backed an advisory resolution on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL27sPl1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638126975","title":"Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638126975","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638126975?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798640,"startTime":"0","endTime":"0","summary":"Esperion (ESPR) announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-presents-new-data-from-clear-outcomes-clear-phase-2-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-presents-new-data-from-clear-outcomes-clear-phase-2-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638851434","title":"Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638851434","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638851434?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300994/0/en/Esperion-Presents-New-Data-from-CLEAR-Outcomes-and-the-CLEAR-PATH-Phase-2-Pediatric-Study-at-the-European-Atherosclerosis-Society-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","LU1861558580.USD","BK4585","BK4588","BK4539","ESPR","PATH","BK4097","BK4551","BK4561","LU1861559042.SGD","BK4547","BK4604","PATX","BK4543","BK4505","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635797725","title":"Esperion grants 260,000 RSUs to 23 new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2635797725","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635797725?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:30","pubTimestamp":1778790649,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics granted 260,000 restricted stock units to 23 new employees on May 12, 2026, under its 2017 Inducement Equity Incentive Plan.RSUs vest 25% on one-year anniversary of vesting commencement date, with remaining 75% vesting in 12 equal quarterly installments, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL9YvZk2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","BK4007","SG9999014013.SGD","SG9999014039.USD","NDAQ","SG9999014021.USD","ESPR","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635257757","title":"Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635257757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635257757?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:30","pubTimestamp":1778790600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA4GY0HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726419","title":"Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726419","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726419?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:30","pubTimestamp":1778790600,"startTime":"0","endTime":"0","summary":"ANN ARBOR, Mich., May  14, 2026  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295421/0/en/Esperion-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","FTEC","QID","SQQQ","ONEQ","GPIQ","QLD","QQQJ","NVIW.SI","TQQQ","QQQM",".IXIC","QQQA","MNQmain","NDX","TECS","TQQY","QYLG","QQQE","PSQ","JEPQ","BK4007","ESPR","IYW","QDTE","QQQ","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635632784","title":"Esperion reports Phase 2 pediatric study shows bempedoic acid lowers LDL-C in HeFH","url":"https://stock-news.laohu8.com/highlight/detail?id=2635632784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635632784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:03","pubTimestamp":1778673808,"startTime":"0","endTime":"0","summary":"Esperion flagged new analyses on bempedoic acid, with results scheduled for presentation May 24-27 at European Atherosclerosis Society Congress 2026 in Athens.Separate analysis from CLEAR Outcomes identified patient characteristics linked to more pronounced LDL-C lowering in statin-intolerant adults, aiming to guide use in clinical practice.Company also slated encore presentations from CLEAR Outcomes analyses on venous thromboembolism risk, stroke incidence, and outcomes without background lipid-lowering therapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1s866n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4585","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","NDAQ","ESPR","SG9999014039.USD","BK4007","BK4112","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082782","title":"Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082782","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635082782?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":"–Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293947/0/en/Esperion-Announces-Two-New-Analyses-Supporting-Bempedoic-Acid-to-Reduce-LDL-C-Levels-to-be-Presented-at-the-European-Atherosclerosis-Society-EAS-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","LDL","ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635892242","title":"Analysts’ Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635892242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635892242?lang=en_us&edition=fundamental","pubTime":"2026-05-13 03:10","pubTimestamp":1778613006,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Passage Bio (PASG) and Esperion (ESPR) with neutral ratings, indicating that the experts are neither ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-passage-bio-pasg-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-passage-bio-pasg-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","ESPR","BK4581","BK4139","LU0128526141.USD","XLV","BK4585","LABU","XBI","HCSG","BK4007","PASG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634449670","title":"Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2634449670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634449670?lang=en_us&edition=fundamental","pubTime":"2026-05-10 14:02","pubTimestamp":1778392935,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has disclosed a new risk, in the Regulation category. The discussion emphasizes that Esperion Therapeutics’ Form 10-Q ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-10-q-forward-looking-statements-highlight-significant-uncertainty-and-investor-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-10-q-forward-looking-statements-highlight-significant-uncertainty-and-investor-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634458734","title":"Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2634458734","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634458734?lang=en_us&edition=fundamental","pubTime":"2026-05-10 10:42","pubTimestamp":1778380977,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/news/esperion-therapeutics-espr-q4-profit-swing-challenges-bearis","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/news/esperion-therapeutics-espr-q4-profit-swing-challenges-bearis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634490362","title":"EXE, IP, ESPR, CMPS, TNXP Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2634490362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634490362?lang=en_us&edition=fundamental","pubTime":"2026-05-09 17:00","pubTimestamp":1778317257,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($EXE) ), ( ($IP) ), ( ($ESPR) ), ( ($CMPS) ) and ( ($TNXP) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/exe-ip-espr-cmps-tnxp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/exe-ip-espr-cmps-tnxp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IP","BK4583","BK4588","LU1169590202.USD","LU1481599808.USD","LU2265009873.SGD","TNXP","BK4007","LU1481600234.SGD","BK4139","ESPR","LU1804176565.USD","CMPS","IE00B3T34201.USD","LU1487256676.USD","EXE","BK4213","LU1169589451.USD","LU2543165471.USD","LU2463526074.USD","BK4136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634920467","title":"Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634920467","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634920467?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:11","pubTimestamp":1778274665,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryEsperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634280464","title":"Esperion Q1 net loss narrows to $25.2 million; product sales rise to $43.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634280464?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:15","pubTimestamp":1778271306,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics posted a net loss of USD 25.2 million, narrowing from USD 40.5 million a year earlier.Net sales rose 24.3% to USD 43.4 million, supported by prescription growth volumes of NEXLETOL and NEXLIZET.Loss from operations narrowed to USD 6.6 million, while research and development expense fell to USD 9 million.Collaboration revenue increased to USD 36.7 million on higher royalty sales growth in partner territories, while interest expense edged up to USD 19.8 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7HQ2vw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992044","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992044?lang=en_us&edition=fundamental","pubTime":"2026-05-05 15:07","pubTimestamp":1777964820,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, OnsemiMay 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4N41I0F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MZTI","PLOO","COIN","PLTY","CBRE","APD","ACMR","ESPR","PLTR","PLTW","ARE","DUOL","NCLH","CRCL","EVER","HUBB","KNSL","AXSM","PLTU","LSCC","BR","CRWG","CORD","ICHR","INSP","GBTG","RBLX","GPI","CONX","WGS","ICOI","DDOG","TGT","CNO","COIW","RBA","AEIS","CLYM","FLGT","CVX","RYAN","LRCX","CRWV","PINS","H","DOGD","AMAT","CHD","DT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992848","title":"BRIEF-BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal  Between $78 Million And $120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992848?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:37","pubTimestamp":1777963063,"startTime":"0","endTime":"0","summary":"BRIEF-BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal  Between $78 Million And $120 MillionMay 5 (Reuters) - BioPharma Credit PLC BPCR.L:BIOPHARMA CREDIT PLC  - STATEMENT RE ARCHIM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUCV2BMQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPCR.UK","BK5078","ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633994306","title":"Biopharma Credit Plc - Co's Allocation of Financing of Esperion Deal  Between $78 Mln and $120 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633994306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633994306?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:00","pubTimestamp":1777960813,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUCV2BMQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5078","ESPR","BK4007","BPCR.UK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":0.0128},{"period":"3month","weight":0.1569},{"period":"6month","weight":-0.2153},{"period":"1year","weight":2.1078},{"period":"ytd","weight":-0.1432}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.039729},{"month":4,"riseRate":0.384615,"avgChangeRate":-0.046726},{"month":5,"riseRate":0.692308,"avgChangeRate":0.013472},{"month":6,"riseRate":0.769231,"avgChangeRate":0.033347},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}